Cargando…

Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial

BACKGROUND: Anacetrapib is the only cholesteryl ester transfer protein inhibitor proven to reduce coronary heart disease (CHD). However, its effects on reverse cholesterol transport have not been fully elucidated. Macrophage cholesterol efflux (CEC), the initial step of reverse cholesterol transport...

Descripción completa

Detalles Bibliográficos
Autores principales:	Metzinger, Mark P., Saldanha, Suzanne, Gulati, Jaskeerat, Patel, Kershaw V., El‐Ghazali, Ayea, Deodhar, Sneha, Joshi, Parag H., Ayers, Colby, Rohatgi, Anand
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955402/ https://www.ncbi.nlm.nih.gov/pubmed/33263263 http://dx.doi.org/10.1161/JAHA.120.018136

Ejemplares similares

Cholesterol efflux capacity and its association with prevalent metabolic syndrome in a multi-ethnic population (Dallas Heart Study)
por: Akinmolayemi, Oludamilola, et al.
Publicado: (2021)

Metabolomic Profiling of Cholesterol Efflux Capacity in a Multiethnic Population: Insights From MESA
por: Hunter, Wynn G., et al.
Publicado: (2023)

Proteomic Determinants of Variation in Cholesterol Efflux: Observations from the Dallas Heart Study
por: Gangwar, Anamika, et al.
Publicado: (2023)

Anacetrapib as a potential cardioprotective strategy
por: Di Bartolo, Belinda A, et al.
Publicado: (2017)

Impact of ADCY9 Genotype on Response to Anacetrapib
por: Hopewell, Jemma C., et al.
Publicado: (2019)

Impaired HDL Metabolism Links GlycA, A Novel Inflammatory Marker, with Incident Cardiovascular Events
por: Riggs, Kayla A., et al.
Publicado: (2019)

GlycA, hsCRP differentially associated with MI, ischemic stroke: In the Dallas Heart Study and Multi-Ethnic Study of Atherosclerosis: GlycA, hsCRP Differentially Associated MI, Stroke
por: Riggs, Kayla A., et al.
Publicado: (2022)

Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin
por: Kühnast, Susan, et al.
Publicado: (2015)

Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?
por: Filippatos, Theodosios D., et al.
Publicado: (2017)

Dalcetrapib and anacetrapib differently impact HDL structure and function in rabbits and monkeys
por: Brodeur, Mathieu R., et al.
Publicado: (2017)

Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease
por: Sammons, E, et al.
Publicado: (2021)

Dalcetrapib and anacetrapib increase apolipoprotein E-containing HDL in rabbits and humans
por: Brodeur, Mathieu R., et al.
Publicado: (2022)

Targeted cholesterol efflux
por: Fang, Longhou, et al.
Publicado: (2013)

Relation of Black Race between High Density Lipoprotein Cholesterol Content, High Density Lipoprotein Particles and Coronary Events (From the Dallas Heart Study)
por: Chandra, Alvin, et al.
Publicado: (2015)

How Anacetrapib Inhibits the Activity of the Cholesteryl Ester Transfer Protein? Perspective through Atomistic Simulations
por: Äijänen, Tarja, et al.
Publicado: (2014)

Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)—A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics
por: Landray, M.J., et al.
Publicado: (2017)

Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib
por: Miyares, Marta A, et al.
Publicado: (2012)

Molecular Mechanisms of Cellular Cholesterol Efflux
por: Phillips, Michael C.
Publicado: (2014)

Cholesterol efflux pathways, inflammation, and atherosclerosis
por: Groenen, Anouk G., et al.
Publicado: (2021)

Reverse Cholesterol Transport Pathway and Cholesterol Efflux in Diabetic Retinopathy
por: Zhang, Xinyuan, et al.
Publicado: (2021)

Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E
por: Millar, John S., et al.
Publicado: (2017)

CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects
por: Thomas, Tiffany, et al.
Publicado: (2017)

Control of Angiogenesis by AIBP-mediated Cholesterol Efflux
por: Fang, Longhou, et al.
Publicado: (2013)

Familial hypercholesterolaemia: cholesterol efflux and coronary disease
por: Versmissen, Jorie, et al.
Publicado: (2016)

Cholesterol Efflux: Does It Contribute to Aortic Stiffening?
por: Liao, Shutan, et al.
Publicado: (2018)

α-Synuclein Regulates Neuronal Cholesterol Efflux
por: Hsiao, Jen-Hsiang T., et al.
Publicado: (2017)

New Strategies to Promote Macrophage Cholesterol Efflux
por: Choi, Hong Y., et al.
Publicado: (2021)

Impact of drug distribution into adipose on tissue function: The cholesteryl ester transfer protein (CETP) inhibitor anacetrapib as a test case
por: Johns, Douglas G., et al.
Publicado: (2019)

Anti-HIV activity of drugs that stimulate cholesterol efflux
por: Morrow, Matthew P, et al.
Publicado: (2006)

Perspective on plasma membrane cholesterol efflux and spermatozoal function
por: Sheriff, Dhastagir Sultan, et al.
Publicado: (2010)

Uremia alters HDL composition and cholesterol efflux capacity
por: Holzer, Michael, et al.
Publicado: (2012)

Voluntary exercise increases cholesterol efflux but not macrophage reverse cholesterol transport in vivo in mice
por: Meissner, Maxi, et al.
Publicado: (2010)

Associations Between High-Density Lipoprotein Particles and Ischemic Events by Vascular Domain, Sex, and Ethnicity: A Pooled Cohort Analysis
por: Singh, Kavisha, et al.
Publicado: (2020)

Guanosine effect on cholesterol efflux and apolipoprotein E expression in astrocytes
por: Ballerini, Patrizia, et al.
Publicado: (2006)

Cholesterol efflux is LXRα isoform-dependent in human macrophages
por: Ma, A Zhi Sha, et al.
Publicado: (2014)

Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis
por: Murphy, Andrew J., et al.
Publicado: (2013)

New insights into the regulation of cholesterol efflux from the sperm membrane
por: Leahy, Tamara, et al.
Publicado: (2015)

Sesamin Enhances Cholesterol Efflux in RAW264.7 Macrophages
por: Liu, Nan, et al.
Publicado: (2014)

Molecular basis of cholesterol efflux via ABCG subfamily transporters
por: Sun, Yingyuan, et al.
Publicado: (2021)

Artesunate attenuates foam cell formation by enhancing cholesterol efflux
por: Qian, Yan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_oj9j0278eva7sqf4glrd38m83n